Summary: Merck is a legacy drugmaker with a history of fat margins and occasional robust
Summary: Merck’s stock has seen a sustained pattern of lower highs and lower lows, with
Summary: Keytruda will overtake Humira as the world’s best-selling drug over the next two years,
Summary: Merck reported positive quarterly earnings with 6.7% year-over-year revenue growth and improved operating margin.
Summary: Merck’s stock has not performed well in the short term, but the long-term outlook
Summary: Merck’s Q3 2023 earnings results will be announced on October 26th. In this preview,
Summary: Merck’s business has been dominated by its oncology drug Keytruda and HPV vaccine Gardasil,
Summary: Despite the increasing number of emerging challenges for the pharmaceutical industry, the management teams
Summary: Keytruda is proving effective in treating more and more types of cancer, and its
Summary: Merck & Co., Inc.’s payout ratios suggest that the market-beating dividend is well-covered. The